TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19850639
Drug: CTC detection
Normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTC detection after chemotherapy
Study: 19850639
Drug: CTC detection
Normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTC detection before neoadjuvant chemotherapy
Study: 18042474
Drug: Buprenorphine transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal delivery system (BTDS)
Study: 8557011
Drug: Rocuronium (0.12,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (0.12, 0.17, 0.22 or 0.27 mg kg‐1, total dose of 0.5 mg kg‐1)
Study: 8557011
Drug: Neostigmine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine administration
Study: 7275464
Drug: 320 kcal
Normalized name: nut.tx for PKU with iron no.41 15 gram-320 kcal/81 gram ORAL BAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 kcal diet with 75 micrograms of T3 daily
Study: 24165020
Drug: Testosterone 2%
Normalized name: TESTOSTERONE 2% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone 2% transdermal gel
Study: 22153256
Drug: Warfarin reinitiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin reinitiation in-hospital
Study: 22153256
Drug: Warfarin reinitiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin reinitiation in selected patients
Study: 22153256
Drug: Factors associated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factors associated with restarting warfarin
Study: 19948753
Drug: Generalized physiotherapy
Normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generalized physiotherapy (G; n = 27)
Study: 16315785
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) 800 microg daily for 6 months
Study: 12455155
Drug: D-003 50
Normalized name: D-panthenol 50
DrugBank: Dexpanthenol (DB09357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-003 50 mg
Study: 12455155
Drug: D-003 50
Normalized name: D-panthenol 50
DrugBank: Dexpanthenol (DB09357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-003 50 mg/day
Study: 12455155
Drug: D-003 5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-003 5, 25 and 50 mg/day
Study: 8749687
Drug: Modeled bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modeled bicarbonate dialysis (M; 28 mmol/L rising to 35 mmol/L at 3 h, 40 mmol/L at 4 h)
Study: 8749687
Drug: High bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High bicarbonate dialysis (H; 40 mmol/L)
Study: 8749687
Drug: Standard bicarbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard bicarbonate dialysis (S; dialysate HCO3- 30 to 34 mmol/L)
Study: 8749687
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (S, H, M)
Study: 2344857
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 1.5 mg digoxin over 6 hours
Study: 2344857
Drug: Bolus injections
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injections of 0.5 mg digoxin 8 hours apart (three injections)
Study: 7407759
Drug: IMPY administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMPY administered via single iv bolus
Study: 7407759
Drug: IMPY administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMPY administered via intermittent 5-day bolus
Study: 7407759
Drug: IMPY administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMPY administered via 5-day continuous infusion
Study: 30177490
Drug: Dihydroergotoxine mesylate
Normalized name: Dihydroergotoxine mesylate
DrugBank: Dihydroergotoxine (DB16602)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotoxine mesylate 2.5 mg orally twice daily
Study: 27996280
Drug: Intravenous MgSO₄
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous MgSO₄
Study: 24219370
Drug: Carrageenan nasal
Normalized name: Carrageenan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrageenan nasal spray, applied three times daily for seven days
Study: 24219370
Drug: Carrageenan nasal
Normalized name: Carrageenan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrageenan nasal spray
Study: 19729979
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel 40 mg/m² (group A)
Study: 19729979
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel 35 mg/m² with gemcitabine 600 mg/m² (group B)
Study: 16424649
Drug: Intravenous anti-D
Normalized name: anti-D (rh) immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anti-D (50 microg/kg i.v. initially, with repeated doses every 4 weeks for 12 patients)
Study: 16424649
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous immunoglobulin (IVIG, 250 mg/kg for 2 consecutive days)
Study: 11006039
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m², Paclitaxel 200 mg/m², Cyclophosphamide 500 mg/m² with G-CSF 300 microg daily for 5 days, followed by Carboplatin AUC-5 and Paclitaxel 135 mg/m²
Study: 1543675
Drug: 1% terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% terbinafine cream
Study: 6337767
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of insulin [2.5 units h‐1 (m2 of body surface area)‐1]
Study: 6337767
Drug: Intravenous angiotensin
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous angiotensin II (20 ng min‐1 kg‐1) with insulin
Study: 6337767
Drug: Intravenous angiotensin
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous angiotensin II (20 ng min‐1 kg‐1) without insulin
Study: 31554423
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 to 600 mg loading dose, 75 mg daily thereafter)
Study: 26143741
Drug: 2.2 g
Normalized name: Vaporizer Safeguard 2.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.2 g marine n-3 polyunsaturated fatty acids (PUFA)
Study: 22341868
Drug: Fenofibrate 200mg
Normalized name: FENOFIBRATE 200MG CAP
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate 200mg daily for 12 weeks
Study: 15881488
Drug: Pioglitazone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone monotherapy and pioglitazone plus sulfonylurea
Study: 12078335
Drug: Carbolithium Once‐A‐Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbolithium Once‐A‐Day (600 mg)
Study: 12078335
Drug: Standard Carbolithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Carbolithium (300 mg b.i.d.)
Study: 23456673
Drug: Tazarotene gel
Normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene gel (3.7 g applied once daily)
Study: 23456673
Drug: Tazarotene foam
Normalized name: tazarotene Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene foam (3.7 g applied once daily)
Study: 23456673
Drug: Tazarotene gel
Normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene gel
Study: 23456673
Drug: Tazarotene foam
Normalized name: tazarotene Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene foam and gel
Study: 21241910
Drug: Brimonidine-timolol fixed
Normalized name: brimonidine / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine-timolol fixed combination, 1 drop immediately after surgery
Study: 15106795
Drug: Drug prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug prescription patterns
Study: 15106795
Drug: Consultations and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consultations and medications
Study: 9850899
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (oxybuprocaine 0.4% drops)
Study: 7861719
Drug: Cyclosporin at
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin at an average dose of 3.9 mg/kg/day for up to three years
Study: 7861719
Drug: Cyclosporin treatment
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin treatment continued for an additional two years
Study: 2682864
Drug: Aerosol inhalation
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol inhalation of salbutamol (SAL)
Study: 2682864
Drug: Aerosol inhalation
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol inhalation of N‐acetyl cysteine (AC)
Study: 2682864
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with aerosol inhalation of SAL and AC followed by CPT (COMB)
Study: 412450
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of sodium etidronate (EHDP)/kg body weight ‐ day for 6 to 24 months
Study: 412450
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of sodium etidronate (EHDP)/kg body weight ‐ day for 6 to 24 months
Study: 412450
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of sodium etidronate (EHDP)/kg body weight ‐ day for 6 to 24 months
Study: 17302257
Drug: Enfuvirtide (ENF)
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enfuvirtide (ENF) 90 mg (1.0 ml)
Study: 17302257
Drug: Enfuvirtide (ENF)
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enfuvirtide (ENF) 45 mg (2 x 0.5 ml)
Study: 17302257
Drug: Injection vehicle
Normalized name: Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NADA fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine Injection [Penmenvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection vehicle (ENF buffer minus ENF)
Study: 10875491
Drug: Topical beclomethasone
Normalized name: beclomethasone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical beclomethasone treatment
Study: 1589705
Drug: Doxycycline triple
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline triple therapy (with bismuth subcitrate and metronidazole)
Study: 1589705
Drug: Tetracycline HCl
Normalized name: tetracycline HCl
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline HCl triple therapy (with bismuth subcitrate and metronidazole)
Study: 22527813
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication therapy (group 1)
Study: 22527813
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication therapy (group 2)
Study: 18006206
Drug: Tray based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tray based whitening system (Colgate Visible White PF Mint) using a 6% hydrogen peroxide gel applied in the tray twice daily for 30 min
Study: 14980755
Drug: Other medical
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other medical therapies (oral contraceptives and/or prostaglandin synthetase inhibitor)
Study: 11777881
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (2-4 g intravenously)
Study: 939070
Drug: Sotalol with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol with diuretic
Study: 27200503
Drug: Metreleptin (0.01,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metreleptin (0.01, 0.1 and 0.3 mg per kg body weight) administered once in a 1-day-long trial
Study: 27200503
Drug: Metreleptin (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metreleptin (0.08 and/or 0.12 mg kg(‐1)) administered for 16 weeks
Study: 27200503
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for 16 weeks
Study: 23146150
Drug: Scopolamine hydrobromide
Normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scopolamine hydrobromide (1 mg/d)
Study: 16086757
Drug: Control (passive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (passive treatments)
Study: 11850863
Drug: 23-valent polysaccharide
Normalized name: pneumococcal 23-valent polysaccharide vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent polysaccharide pneumococcal vaccine
Study: 7487465
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir during ALA therapy (group 1)
Study: 6127719
Drug: ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ipratropium bromide (160 micrograms daily)
Study: 6127719
Drug: thiazinamium methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: thiazinamium methyl sulphate (900 mg daily)
Study: 27814302
Drug: Stimulant medication
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant medication (dosage titrated by physician)
Study: 17335691
Drug: Myeloid growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myeloid growth factors (MGFs) used at varied schedules, doses, and durations differing from FDA approved prescribing information.
Study: 17335691
Drug: Myeloid growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myeloid growth factors (MGFs) administered on the same day as chemotherapy.
Study: 16291353
Drug: Hood (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hood (1.5 mg epinephrine in 4 mL saline [3%])
Study: 16291353
Drug: Mask (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mask (1.5 mg epinephrine in 4 mL saline [3%])
Study: 10460118
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy interventions (physical function, social and leisure activities, other)
Study: 10460118
Drug: Median treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Median treatment time for a session
Study: 10460118
Drug: Variability in
Normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variability in treatment delivery
Study: 7528271
Drug: ICE chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICE chemotherapy with G‐CSF
Study: 2381617
Drug: 2% clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% clindamycin cream
Study: 2381617
Drug: Lower concentrations
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower concentrations of clindamycin cream (0.1% and 1%)
Study: 23224127
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) early treatment (IVB1)
Study: 23224127
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone (IVT) early treatment (IVT1)
Study: 23224127
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) late treatment (IVB2)
Study: 23224127
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone (IVT) late treatment (IVT2)
Study: 18165205
Drug: Placebo (other
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (other drug than spironolactone)
Study: 10954340
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (25 g in 200 ml water)
Study: 10718784
Drug: Water (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (200 ml) (control)
Study: 9177508
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of endoscopic variceal ligation (EVL) and endoscopic sclerotherapy (EST)
Study: 8415265
Drug: Budesonide forte
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide forte aerosol Polfa, 200 micrograms four times daily
Study: 21087288
Drug: NETE-8 (norethisterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: NETE-8 (norethisterone enanthate 200 mg every 8 weeks plus testosterone undecanoate 1000 mg)
Study: 21087288
Drug: NETE-6/12 (norethisterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: NETE-6/12 (norethisterone enanthate 200 mg every 6 weeks for 12 weeks and then every 12 weeks plus testosterone undecanoate 1000 mg)
Study: 21087288
Drug: NETE-6/12/0 (norethisterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: NETE-6/12/0 (norethisterone enanthate 200 mg every 6 weeks for 12 weeks and then testosterone undecanoate plus placebo every 12 weeks)
Study: 16995976
Drug: Combined non-biological
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined non-biological artificial liver treatment
Study: 16995976
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no combined non-biological artificial liver treatment)
Study: 9024169
Drug: Triazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.5 mg) after rifampin (600 mg once daily for 5 days)
Study: 8101045
Drug: Flumazenil administered
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumazenil administered intravenously in small, incremental doses
Study: 24956863
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (surgical treatment + chemotherapy regimen PTX + EPI + CTX)
Study: 21131072
Drug: PCI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCI with tirofiban infusion (TI)
Study: 21131072
Drug: PCI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCI with both treatments (IT+TI)
Study: 21131072
Drug: Tirofiban infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban infusion (TI)
Study: 16324409
Drug: Glucosamine hydrochloride
Normalized name: Glucosamine Hydrochloride
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine hydrochloride (GH) 1440 mg/day for 4 weeks
Study: 16324409
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulfate (GS) 1500 mg/day for 4 weeks
Study: 12934980
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg/day increased to 60 mg/day)
Study: 12934980
Drug: Citalopram (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (continued treatment)
Study: 10848459
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (patrol response)
Study: 8848916
Drug: Intrathecal (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal (0.4 mg) and intramuscular (4 mg) morphine (IT‐IM‐group)
Study: 8848916
Drug: Intrathecal (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal (0.4 mg) morphine and intramuscular saline (IT‐group)
Study: 8848916
Drug: Intrathecal (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal (0.4 mg) morphine (IT‐group)
Study: 6438851
Drug: Ifosfamide (IF)
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide (IF) at 1.8 g/m2 days 1‐5 q 4 weeks with Mesna (0.36 g/m2 i.v. or 0.72 g/m2 orally) given after each IF injection.
Study: 6438851
Drug: Ifosfamide +
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide + Mesna combination
Study: 30967589
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy sessions
Study: 12039990
Drug: Active vitamin
Normalized name: OCTOCRYLENE 70 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTISALATE 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL TOPICAL CREAM [Garnier SkinActive Vitamin(E) C UV Brightening Daily Broad Spectrum SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active vitamin D (0.25 microg/d) plus calcium (1000 mg/d)
Study: 12039990
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (NoT group)
Study: 7981510
Drug: Superparamagnetic iron
Normalized name: Superparamagnetic iron oxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superparamagnetic iron oxide (SHU 555 A) at doses of 5, 10, 20, and 40 mumol/kg
Study: 2689345
Drug: Aztreonam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam (1 g i.v. bolus t.i.d. for a mean of 8.2 days)